Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥587.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥12.06B
Enterprise Value¥12.28K
Total Cash (Recent Filing)¥3.96B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA debt-free balance sheet with roughly ¥4.37B of equity provides durable financial flexibility. This reduces bankruptcy risk, supports continued investment or R&D while losses persist, and gives the company options (internal funding, partnerships) to finance a multi-quarter recovery without immediate solvency pressure.
High Gross MarginsExceptionally high gross margins indicate strong unit economics and scalability of core services. If operating costs are rationalized, these margins enable rapid progress to profitability as revenue scales, allowing incremental revenue to translate efficiently into improved operating results over multiple quarters.
Revenue RecoveryThe return to year-over-year revenue growth signals regained traction in product-market fit and demand. Sustained top-line recovery provides a platform to leverage high gross margins and operating leverage, making multi-quarter improvements in margins and cash flow achievable if growth continues.
Bears Say
Worsening Cash BurnMaterial negative operating and free cash flow indicate the company is consuming cash faster over time, creating a durable funding need. Even with no debt, persistent cash burn forces reliance on equity financing or asset sales, risks dilution, and can constrain strategic investments or recovery plans across multiple quarters.
Deep UnprofitabilityVery large negative net margins show operating costs far outstrip revenues, reflecting structural profitability challenges. Without sustained revenue growth and operating expense control, losses will persist, limiting reinvestment capacity and prolonging reliance on external funding over the medium term.
Erosion Of EquityDeclining shareholders' equity despite zero debt means the balance sheet buffer is being eroded by losses. Continued erosion reduces long-term financial resilience and may necessitate capital raises that dilute ownership or alter capital structure, weakening the firm’s ability to fund a sustained turnaround.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥587.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥12.06B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on May 08, 2026. The company reported -¥3.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.54.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥3.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.611%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.